Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
Medical ImagingMolecular Imaging

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1798889

Cover Image

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1798889

Gadoquatrane

PUBLISHED:
PAGES: 273 Pages
DELIVERY TIME: 1-2 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
PDF & Excel (Single User License)
USD 5850
PDF & Excel (Global License to Company and its Fully-owned Subsidiaries)
USD 17550

Add to Cart

Description

Table of Contents

Global Gadoquatrane Market to Reach US$2.4 Billion by 2030

The global market for Gadoquatrane estimated at US$1.9 Billion in the year 2024, is expected to reach US$2.4 Billion by 2030, growing at a CAGR of 3.4% over the analysis period 2024-2030. Screening Application, one of the segments analyzed in the report, is expected to record a 2.7% CAGR and reach US$1.4 Billion by the end of the analysis period. Growth in the Diagnosis Application segment is estimated at 4.6% CAGR over the analysis period.

The U.S. Market is Estimated at US$527.8 Million While China is Forecast to Grow at 6.2% CAGR

The Gadoquatrane market in the U.S. is estimated at US$527.8 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$466.2 Million by the year 2030 trailing a CAGR of 6.2% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.4% and 2.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.9% CAGR.

Global Gadoquatrane Market - Key Trends & Drivers Summarized

Why Is Gadoquatrane Gaining Attention in Diagnostic Imaging?

Gadoquatrane is a next-generation macrocyclic gadolinium-based contrast agent (GBCA) used in magnetic resonance imaging (MRI). It has been developed to offer improved imaging performance with enhanced safety features, particularly for patients requiring repeated scans. Gadoquatrane’s molecular structure provides strong binding of gadolinium ions, minimizing the risk of dissociation and reducing the likelihood of gadolinium retention in tissues. This has become an important consideration following concerns over long-term gadolinium accumulation associated with earlier-generation contrast agents.

In clinical practice, gadoquatrane is used to enhance visualization of blood vessels, organs, and pathological structures such as tumors and lesions. Its strong relaxivity properties support high-resolution imaging at lower doses, which is especially valuable in pediatric and renal-impaired patients. As demand for accurate, high-contrast MRI continues to rise in neurology, oncology, and cardiovascular diagnostics, gadoquatrane is increasingly viewed as a safer alternative with superior diagnostic clarity. The product is being adopted by radiology departments aiming to balance image quality with patient safety.

How Are Formulation Advances and Safety Profiles Supporting Adoption?

Macrocyclic contrast agents like gadoquatrane are known for their chemical stability and low propensity to release free gadolinium ions. Gadoquatrane builds on this foundation by offering enhanced kinetic inertness and reduced risk of nephrogenic systemic fibrosis (NSF), a rare but serious condition linked to gadolinium in patients with impaired kidney function. These characteristics are being emphasized in regulatory filings and clinical protocols, making gadoquatrane suitable for broader patient groups.

Another factor aiding adoption is the agent’s high relaxivity at clinical field strengths, which allows for shorter scan times and sharper image contrasts. This enables more efficient imaging workflows and greater diagnostic precision in detecting soft tissue abnormalities. Compatibility with standard MRI equipment and contrast delivery systems allows seamless integration into existing imaging setups, making it easier for healthcare providers to transition without significant infrastructure upgrades.

What Clinical and Regulatory Trends Are Shaping Market Potential?

MRI scan volumes continue to increase globally, driven by rising incidence of neurological disorders, cancer screening, and cardiovascular disease evaluation. These trends are leading healthcare providers to seek contrast agents that offer superior image quality with minimal safety concerns. Regulatory bodies are increasingly focusing on contrast agent safety, encouraging the use of agents with lower gadolinium release risk. Gadoquatrane aligns well with such preferences, positioning it as a preferred option for hospitals and diagnostic imaging centers.

Institutional adoption is supported by growing inclusion of macrocyclic agents in clinical guidelines and purchasing frameworks. Reimbursement policies that favor advanced diagnostic procedures also support wider uptake, particularly in developed markets. As awareness around gadolinium retention grows among clinicians and patients, demand for safer contrast solutions is expected to continue rising. Ongoing clinical studies are expanding the scope of gadoquatrane in specialized imaging applications, such as CNS lesion detection and pediatric radiology.

Growth in the Gadoquatrane Market Is Driven by Several Factors…

Growth in the gadoquatrane market is driven by several factors including increasing demand for safer gadolinium-based MRI contrast agents, expanding diagnostic imaging volumes, and technological improvements in agent formulation. Rising concern over tissue retention of gadolinium is prompting a shift toward macrocyclic compounds with higher kinetic stability. Gadoquatrane’s ability to deliver high relaxivity at low doses supports improved imaging outcomes in neurology, oncology, and vascular diagnostics. Regulatory support for low-risk contrast agents and alignment with evolving safety standards facilitate market expansion across hospital and outpatient settings. As healthcare providers seek efficient, high-resolution imaging tools with proven safety profiles, gadoquatrane is gaining traction as a next-generation option in advanced MRI diagnostics.

SCOPE OF STUDY:

The report analyzes the Gadoquatrane market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Application (Screening Application, Diagnosis Application); End-User (Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User, Other End-Users)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 36 Featured) -

  • Bayer AG
  • Bracco Imaging S.p.A.
  • Canon Medical Systems
  • Curium Pharma
  • FUJIFILM Holdings Corporation
  • GE Healthcare
  • Glenmark Pharmaceuticals
  • Guerbet Group
  • Hitachi Medical Systems
  • Lantheus Medical Imaging
  • Mallinckrodt Pharmaceuticals
  • Nihon Medi-Physics
  • Philips Healthcare
  • Siemens Healthineers
  • Sinerga S.p.A.
  • Shenzhen YHLO Biotech
  • Simcere Pharmaceutical Group
  • Shenzhen Wanliyang Medical
  • Troikaa Pharmaceuticals
  • Unistar Medical

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

Show more
Product Code: MCP38862

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Gadoquatrane - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Demand for Safer and More Stable MRI Contrast Agents Drives Clinical Interest in Gadoquatrane Formulations
    • Increased Concerns Over Gadolinium Retention in Patients With Renal Impairment Spur Development of Macrocyclic Agents Like Gadoquatrane
    • Growth in MRI Procedures Across Oncology, Neurology, and Cardiovascular Imaging Supports Adoption of Novel Contrast Agents
    • Advancements in Contrast Agent Design Enhance Stability, Relaxivity, and Diagnostic Accuracy in Gadoquatrane-Based Products
    • Surge in Gadolinium-Free and Low-Dose Alternatives Positions Gadoquatrane as a Viable Macrocyclic Solution With Enhanced Safety Margins
    • Expansion of Pediatric and Geriatric Imaging Services Highlights Demand for Well-Tolerated, Low-Toxicity Contrast Media
    • Improved Shelf-Life, Storage Stability, and Compatibility With MRI Modalities Support Hospital Adoption of Gadoquatrane
    • Increasing Investment in Radiopharmaceutical R&D Creates Opportunities for Dual-Function Imaging and Contrast Agents
    • Use in High-Resolution Brain and Vascular Imaging Scenarios Expands Clinical Applications for Gadoquatrane-Based Products
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Gadoquatrane Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Gadoquatrane by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Gadoquatrane by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 4: World 16-Year Perspective for Gadoquatrane by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Screening Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Screening Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 7: World 16-Year Perspective for Screening Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Diagnosis Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Diagnosis Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 10: World 16-Year Perspective for Diagnosis Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Hospitals End-User by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Hospitals End-User by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 13: World 16-Year Perspective for Hospitals End-User by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Diagnostic Centers End-User by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Diagnostic Centers End-User by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 16: World 16-Year Perspective for Diagnostic Centers End-User by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Specialty Clinics End-User by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Specialty Clinics End-User by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 19: World 16-Year Perspective for Specialty Clinics End-User by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Other End-Users by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Other End-Users by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 22: World 16-Year Perspective for Other End-Users by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Gadoquatrane Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 23: USA Recent Past, Current & Future Analysis for Gadoquatrane by Application - Screening Application and Diagnosis Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 24: USA Historic Review for Gadoquatrane by Application - Screening Application and Diagnosis Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 25: USA 16-Year Perspective for Gadoquatrane by Application - Percentage Breakdown of Value Sales for Screening Application and Diagnosis Application for the Years 2014, 2025 & 2030
    • TABLE 26: USA Recent Past, Current & Future Analysis for Gadoquatrane by End-user - Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 27: USA Historic Review for Gadoquatrane by End-user - Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 28: USA 16-Year Perspective for Gadoquatrane by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030
  • CANADA
    • TABLE 29: Canada Recent Past, Current & Future Analysis for Gadoquatrane by Application - Screening Application and Diagnosis Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 30: Canada Historic Review for Gadoquatrane by Application - Screening Application and Diagnosis Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 31: Canada 16-Year Perspective for Gadoquatrane by Application - Percentage Breakdown of Value Sales for Screening Application and Diagnosis Application for the Years 2014, 2025 & 2030
    • TABLE 32: Canada Recent Past, Current & Future Analysis for Gadoquatrane by End-user - Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Canada Historic Review for Gadoquatrane by End-user - Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 34: Canada 16-Year Perspective for Gadoquatrane by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030
  • JAPAN
    • Gadoquatrane Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 35: Japan Recent Past, Current & Future Analysis for Gadoquatrane by Application - Screening Application and Diagnosis Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Japan Historic Review for Gadoquatrane by Application - Screening Application and Diagnosis Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 37: Japan 16-Year Perspective for Gadoquatrane by Application - Percentage Breakdown of Value Sales for Screening Application and Diagnosis Application for the Years 2014, 2025 & 2030
    • TABLE 38: Japan Recent Past, Current & Future Analysis for Gadoquatrane by End-user - Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Japan Historic Review for Gadoquatrane by End-user - Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 40: Japan 16-Year Perspective for Gadoquatrane by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030
  • CHINA
    • Gadoquatrane Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 41: China Recent Past, Current & Future Analysis for Gadoquatrane by Application - Screening Application and Diagnosis Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 42: China Historic Review for Gadoquatrane by Application - Screening Application and Diagnosis Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 43: China 16-Year Perspective for Gadoquatrane by Application - Percentage Breakdown of Value Sales for Screening Application and Diagnosis Application for the Years 2014, 2025 & 2030
    • TABLE 44: China Recent Past, Current & Future Analysis for Gadoquatrane by End-user - Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 45: China Historic Review for Gadoquatrane by End-user - Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 46: China 16-Year Perspective for Gadoquatrane by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030
  • EUROPE
    • Gadoquatrane Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 47: Europe Recent Past, Current & Future Analysis for Gadoquatrane by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 48: Europe Historic Review for Gadoquatrane by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 49: Europe 16-Year Perspective for Gadoquatrane by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Gadoquatrane by Application - Screening Application and Diagnosis Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Europe Historic Review for Gadoquatrane by Application - Screening Application and Diagnosis Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 52: Europe 16-Year Perspective for Gadoquatrane by Application - Percentage Breakdown of Value Sales for Screening Application and Diagnosis Application for the Years 2014, 2025 & 2030
    • TABLE 53: Europe Recent Past, Current & Future Analysis for Gadoquatrane by End-user - Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Europe Historic Review for Gadoquatrane by End-user - Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 55: Europe 16-Year Perspective for Gadoquatrane by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030
  • FRANCE
    • Gadoquatrane Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 56: France Recent Past, Current & Future Analysis for Gadoquatrane by Application - Screening Application and Diagnosis Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: France Historic Review for Gadoquatrane by Application - Screening Application and Diagnosis Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 58: France 16-Year Perspective for Gadoquatrane by Application - Percentage Breakdown of Value Sales for Screening Application and Diagnosis Application for the Years 2014, 2025 & 2030
    • TABLE 59: France Recent Past, Current & Future Analysis for Gadoquatrane by End-user - Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 60: France Historic Review for Gadoquatrane by End-user - Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 61: France 16-Year Perspective for Gadoquatrane by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030
  • GERMANY
    • Gadoquatrane Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 62: Germany Recent Past, Current & Future Analysis for Gadoquatrane by Application - Screening Application and Diagnosis Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Germany Historic Review for Gadoquatrane by Application - Screening Application and Diagnosis Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 64: Germany 16-Year Perspective for Gadoquatrane by Application - Percentage Breakdown of Value Sales for Screening Application and Diagnosis Application for the Years 2014, 2025 & 2030
    • TABLE 65: Germany Recent Past, Current & Future Analysis for Gadoquatrane by End-user - Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Germany Historic Review for Gadoquatrane by End-user - Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 67: Germany 16-Year Perspective for Gadoquatrane by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030
  • ITALY
    • TABLE 68: Italy Recent Past, Current & Future Analysis for Gadoquatrane by Application - Screening Application and Diagnosis Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Italy Historic Review for Gadoquatrane by Application - Screening Application and Diagnosis Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 70: Italy 16-Year Perspective for Gadoquatrane by Application - Percentage Breakdown of Value Sales for Screening Application and Diagnosis Application for the Years 2014, 2025 & 2030
    • TABLE 71: Italy Recent Past, Current & Future Analysis for Gadoquatrane by End-user - Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Italy Historic Review for Gadoquatrane by End-user - Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 73: Italy 16-Year Perspective for Gadoquatrane by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030
  • UNITED KINGDOM
    • Gadoquatrane Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 74: UK Recent Past, Current & Future Analysis for Gadoquatrane by Application - Screening Application and Diagnosis Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 75: UK Historic Review for Gadoquatrane by Application - Screening Application and Diagnosis Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 76: UK 16-Year Perspective for Gadoquatrane by Application - Percentage Breakdown of Value Sales for Screening Application and Diagnosis Application for the Years 2014, 2025 & 2030
    • TABLE 77: UK Recent Past, Current & Future Analysis for Gadoquatrane by End-user - Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 78: UK Historic Review for Gadoquatrane by End-user - Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 79: UK 16-Year Perspective for Gadoquatrane by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030
  • SPAIN
    • TABLE 80: Spain Recent Past, Current & Future Analysis for Gadoquatrane by Application - Screening Application and Diagnosis Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Spain Historic Review for Gadoquatrane by Application - Screening Application and Diagnosis Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 82: Spain 16-Year Perspective for Gadoquatrane by Application - Percentage Breakdown of Value Sales for Screening Application and Diagnosis Application for the Years 2014, 2025 & 2030
    • TABLE 83: Spain Recent Past, Current & Future Analysis for Gadoquatrane by End-user - Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Spain Historic Review for Gadoquatrane by End-user - Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 85: Spain 16-Year Perspective for Gadoquatrane by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030
  • RUSSIA
    • TABLE 86: Russia Recent Past, Current & Future Analysis for Gadoquatrane by Application - Screening Application and Diagnosis Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Russia Historic Review for Gadoquatrane by Application - Screening Application and Diagnosis Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 88: Russia 16-Year Perspective for Gadoquatrane by Application - Percentage Breakdown of Value Sales for Screening Application and Diagnosis Application for the Years 2014, 2025 & 2030
    • TABLE 89: Russia Recent Past, Current & Future Analysis for Gadoquatrane by End-user - Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Russia Historic Review for Gadoquatrane by End-user - Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 91: Russia 16-Year Perspective for Gadoquatrane by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030
  • REST OF EUROPE
    • TABLE 92: Rest of Europe Recent Past, Current & Future Analysis for Gadoquatrane by Application - Screening Application and Diagnosis Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Rest of Europe Historic Review for Gadoquatrane by Application - Screening Application and Diagnosis Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 94: Rest of Europe 16-Year Perspective for Gadoquatrane by Application - Percentage Breakdown of Value Sales for Screening Application and Diagnosis Application for the Years 2014, 2025 & 2030
    • TABLE 95: Rest of Europe Recent Past, Current & Future Analysis for Gadoquatrane by End-user - Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Rest of Europe Historic Review for Gadoquatrane by End-user - Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 97: Rest of Europe 16-Year Perspective for Gadoquatrane by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030
  • ASIA-PACIFIC
    • Gadoquatrane Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 98: Asia-Pacific Recent Past, Current & Future Analysis for Gadoquatrane by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 99: Asia-Pacific Historic Review for Gadoquatrane by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 100: Asia-Pacific 16-Year Perspective for Gadoquatrane by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
    • TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for Gadoquatrane by Application - Screening Application and Diagnosis Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Asia-Pacific Historic Review for Gadoquatrane by Application - Screening Application and Diagnosis Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 103: Asia-Pacific 16-Year Perspective for Gadoquatrane by Application - Percentage Breakdown of Value Sales for Screening Application and Diagnosis Application for the Years 2014, 2025 & 2030
    • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Gadoquatrane by End-user - Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Asia-Pacific Historic Review for Gadoquatrane by End-user - Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 106: Asia-Pacific 16-Year Perspective for Gadoquatrane by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030
  • AUSTRALIA
    • Gadoquatrane Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 107: Australia Recent Past, Current & Future Analysis for Gadoquatrane by Application - Screening Application and Diagnosis Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Australia Historic Review for Gadoquatrane by Application - Screening Application and Diagnosis Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 109: Australia 16-Year Perspective for Gadoquatrane by Application - Percentage Breakdown of Value Sales for Screening Application and Diagnosis Application for the Years 2014, 2025 & 2030
    • TABLE 110: Australia Recent Past, Current & Future Analysis for Gadoquatrane by End-user - Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Australia Historic Review for Gadoquatrane by End-user - Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 112: Australia 16-Year Perspective for Gadoquatrane by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030
  • INDIA
    • Gadoquatrane Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 113: India Recent Past, Current & Future Analysis for Gadoquatrane by Application - Screening Application and Diagnosis Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 114: India Historic Review for Gadoquatrane by Application - Screening Application and Diagnosis Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 115: India 16-Year Perspective for Gadoquatrane by Application - Percentage Breakdown of Value Sales for Screening Application and Diagnosis Application for the Years 2014, 2025 & 2030
    • TABLE 116: India Recent Past, Current & Future Analysis for Gadoquatrane by End-user - Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 117: India Historic Review for Gadoquatrane by End-user - Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 118: India 16-Year Perspective for Gadoquatrane by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030
  • SOUTH KOREA
    • TABLE 119: South Korea Recent Past, Current & Future Analysis for Gadoquatrane by Application - Screening Application and Diagnosis Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 120: South Korea Historic Review for Gadoquatrane by Application - Screening Application and Diagnosis Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 121: South Korea 16-Year Perspective for Gadoquatrane by Application - Percentage Breakdown of Value Sales for Screening Application and Diagnosis Application for the Years 2014, 2025 & 2030
    • TABLE 122: South Korea Recent Past, Current & Future Analysis for Gadoquatrane by End-user - Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 123: South Korea Historic Review for Gadoquatrane by End-user - Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 124: South Korea 16-Year Perspective for Gadoquatrane by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 125: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Gadoquatrane by Application - Screening Application and Diagnosis Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Rest of Asia-Pacific Historic Review for Gadoquatrane by Application - Screening Application and Diagnosis Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 127: Rest of Asia-Pacific 16-Year Perspective for Gadoquatrane by Application - Percentage Breakdown of Value Sales for Screening Application and Diagnosis Application for the Years 2014, 2025 & 2030
    • TABLE 128: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Gadoquatrane by End-user - Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Rest of Asia-Pacific Historic Review for Gadoquatrane by End-user - Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 130: Rest of Asia-Pacific 16-Year Perspective for Gadoquatrane by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030
  • LATIN AMERICA
    • Gadoquatrane Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 131: Latin America Recent Past, Current & Future Analysis for Gadoquatrane by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 132: Latin America Historic Review for Gadoquatrane by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 133: Latin America 16-Year Perspective for Gadoquatrane by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
    • TABLE 134: Latin America Recent Past, Current & Future Analysis for Gadoquatrane by Application - Screening Application and Diagnosis Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Latin America Historic Review for Gadoquatrane by Application - Screening Application and Diagnosis Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 136: Latin America 16-Year Perspective for Gadoquatrane by Application - Percentage Breakdown of Value Sales for Screening Application and Diagnosis Application for the Years 2014, 2025 & 2030
    • TABLE 137: Latin America Recent Past, Current & Future Analysis for Gadoquatrane by End-user - Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Latin America Historic Review for Gadoquatrane by End-user - Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 139: Latin America 16-Year Perspective for Gadoquatrane by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030
  • ARGENTINA
    • TABLE 140: Argentina Recent Past, Current & Future Analysis for Gadoquatrane by Application - Screening Application and Diagnosis Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Argentina Historic Review for Gadoquatrane by Application - Screening Application and Diagnosis Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 142: Argentina 16-Year Perspective for Gadoquatrane by Application - Percentage Breakdown of Value Sales for Screening Application and Diagnosis Application for the Years 2014, 2025 & 2030
    • TABLE 143: Argentina Recent Past, Current & Future Analysis for Gadoquatrane by End-user - Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Argentina Historic Review for Gadoquatrane by End-user - Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 145: Argentina 16-Year Perspective for Gadoquatrane by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030
  • BRAZIL
    • TABLE 146: Brazil Recent Past, Current & Future Analysis for Gadoquatrane by Application - Screening Application and Diagnosis Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Brazil Historic Review for Gadoquatrane by Application - Screening Application and Diagnosis Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 148: Brazil 16-Year Perspective for Gadoquatrane by Application - Percentage Breakdown of Value Sales for Screening Application and Diagnosis Application for the Years 2014, 2025 & 2030
    • TABLE 149: Brazil Recent Past, Current & Future Analysis for Gadoquatrane by End-user - Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Brazil Historic Review for Gadoquatrane by End-user - Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 151: Brazil 16-Year Perspective for Gadoquatrane by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030
  • MEXICO
    • TABLE 152: Mexico Recent Past, Current & Future Analysis for Gadoquatrane by Application - Screening Application and Diagnosis Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Mexico Historic Review for Gadoquatrane by Application - Screening Application and Diagnosis Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 154: Mexico 16-Year Perspective for Gadoquatrane by Application - Percentage Breakdown of Value Sales for Screening Application and Diagnosis Application for the Years 2014, 2025 & 2030
    • TABLE 155: Mexico Recent Past, Current & Future Analysis for Gadoquatrane by End-user - Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Mexico Historic Review for Gadoquatrane by End-user - Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 157: Mexico 16-Year Perspective for Gadoquatrane by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 158: Rest of Latin America Recent Past, Current & Future Analysis for Gadoquatrane by Application - Screening Application and Diagnosis Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Rest of Latin America Historic Review for Gadoquatrane by Application - Screening Application and Diagnosis Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 160: Rest of Latin America 16-Year Perspective for Gadoquatrane by Application - Percentage Breakdown of Value Sales for Screening Application and Diagnosis Application for the Years 2014, 2025 & 2030
    • TABLE 161: Rest of Latin America Recent Past, Current & Future Analysis for Gadoquatrane by End-user - Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Rest of Latin America Historic Review for Gadoquatrane by End-user - Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 163: Rest of Latin America 16-Year Perspective for Gadoquatrane by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030
  • MIDDLE EAST
    • Gadoquatrane Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 164: Middle East Recent Past, Current & Future Analysis for Gadoquatrane by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 165: Middle East Historic Review for Gadoquatrane by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 166: Middle East 16-Year Perspective for Gadoquatrane by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
    • TABLE 167: Middle East Recent Past, Current & Future Analysis for Gadoquatrane by Application - Screening Application and Diagnosis Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Middle East Historic Review for Gadoquatrane by Application - Screening Application and Diagnosis Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 169: Middle East 16-Year Perspective for Gadoquatrane by Application - Percentage Breakdown of Value Sales for Screening Application and Diagnosis Application for the Years 2014, 2025 & 2030
    • TABLE 170: Middle East Recent Past, Current & Future Analysis for Gadoquatrane by End-user - Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Middle East Historic Review for Gadoquatrane by End-user - Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 172: Middle East 16-Year Perspective for Gadoquatrane by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030
  • IRAN
    • TABLE 173: Iran Recent Past, Current & Future Analysis for Gadoquatrane by Application - Screening Application and Diagnosis Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Iran Historic Review for Gadoquatrane by Application - Screening Application and Diagnosis Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 175: Iran 16-Year Perspective for Gadoquatrane by Application - Percentage Breakdown of Value Sales for Screening Application and Diagnosis Application for the Years 2014, 2025 & 2030
    • TABLE 176: Iran Recent Past, Current & Future Analysis for Gadoquatrane by End-user - Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Iran Historic Review for Gadoquatrane by End-user - Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 178: Iran 16-Year Perspective for Gadoquatrane by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030
  • ISRAEL
    • TABLE 179: Israel Recent Past, Current & Future Analysis for Gadoquatrane by Application - Screening Application and Diagnosis Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Israel Historic Review for Gadoquatrane by Application - Screening Application and Diagnosis Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 181: Israel 16-Year Perspective for Gadoquatrane by Application - Percentage Breakdown of Value Sales for Screening Application and Diagnosis Application for the Years 2014, 2025 & 2030
    • TABLE 182: Israel Recent Past, Current & Future Analysis for Gadoquatrane by End-user - Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Israel Historic Review for Gadoquatrane by End-user - Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 184: Israel 16-Year Perspective for Gadoquatrane by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 185: Saudi Arabia Recent Past, Current & Future Analysis for Gadoquatrane by Application - Screening Application and Diagnosis Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Saudi Arabia Historic Review for Gadoquatrane by Application - Screening Application and Diagnosis Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 187: Saudi Arabia 16-Year Perspective for Gadoquatrane by Application - Percentage Breakdown of Value Sales for Screening Application and Diagnosis Application for the Years 2014, 2025 & 2030
    • TABLE 188: Saudi Arabia Recent Past, Current & Future Analysis for Gadoquatrane by End-user - Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Saudi Arabia Historic Review for Gadoquatrane by End-user - Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 190: Saudi Arabia 16-Year Perspective for Gadoquatrane by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 191: UAE Recent Past, Current & Future Analysis for Gadoquatrane by Application - Screening Application and Diagnosis Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 192: UAE Historic Review for Gadoquatrane by Application - Screening Application and Diagnosis Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 193: UAE 16-Year Perspective for Gadoquatrane by Application - Percentage Breakdown of Value Sales for Screening Application and Diagnosis Application for the Years 2014, 2025 & 2030
    • TABLE 194: UAE Recent Past, Current & Future Analysis for Gadoquatrane by End-user - Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 195: UAE Historic Review for Gadoquatrane by End-user - Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 196: UAE 16-Year Perspective for Gadoquatrane by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 197: Rest of Middle East Recent Past, Current & Future Analysis for Gadoquatrane by Application - Screening Application and Diagnosis Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Rest of Middle East Historic Review for Gadoquatrane by Application - Screening Application and Diagnosis Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 199: Rest of Middle East 16-Year Perspective for Gadoquatrane by Application - Percentage Breakdown of Value Sales for Screening Application and Diagnosis Application for the Years 2014, 2025 & 2030
    • TABLE 200: Rest of Middle East Recent Past, Current & Future Analysis for Gadoquatrane by End-user - Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Rest of Middle East Historic Review for Gadoquatrane by End-user - Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 202: Rest of Middle East 16-Year Perspective for Gadoquatrane by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030
  • AFRICA
    • Gadoquatrane Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 203: Africa Recent Past, Current & Future Analysis for Gadoquatrane by Application - Screening Application and Diagnosis Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Africa Historic Review for Gadoquatrane by Application - Screening Application and Diagnosis Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 205: Africa 16-Year Perspective for Gadoquatrane by Application - Percentage Breakdown of Value Sales for Screening Application and Diagnosis Application for the Years 2014, 2025 & 2030
    • TABLE 206: Africa Recent Past, Current & Future Analysis for Gadoquatrane by End-user - Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Africa Historic Review for Gadoquatrane by End-user - Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 208: Africa 16-Year Perspective for Gadoquatrane by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030

IV. COMPETITION

Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!